Working together to set research priorities for NASH with an optimal contribution of biobanks

Thanks to a dialogue with and between all the parties involved - patients and families, doctors and caregivers, researchers, biobanks, pharmaceutical and biotechnology companies - we have

• prioritised present and future research topics regarding NASH (non-alcoholic steatohepatitis), for which biobanks can be a decisive asset;

• identified the challenges which will confront biobanks in the future taking account of the views of the various parties involved.

This report represents a call for the development of research on the major public-health challenge that NASH represents as well as an encouragement to continue the dialogue between the biobank stakeholders. The biobanks must obviously be considered as a common indispensable research asset.